Zoetis Launches SimparicaTM (sarolaner) in Europe

  • Persistent and highly effective oral medication against a broad spectrum of ectoparasites in dogs beginning at eight weeks of age
  • Tasty chewable tablet for once-monthly administration
  • Immediate onset with peak performance against fleas and ticks lasting for full 35 days, without losing efficacy at the end of the month
  • Indicated for treatment of sarcoptic mange and Flea Allergy Dermatitis (FAD)
  • Well tolerated with an excellent safety profile in dogs of all breeds from 8 week of age

AMSTERDAM, NETHERLANDS, April 5, 2016 – Zoetis Inc. today announced the European launch of SimparicaTM (sarolaner), a once-monthly oral medication for the treatment of flea, tick and mite infestations in dogs beginning at eight weeks of age. Simparica acts quickly and provides continuous protection for 35 days without losing efficacy at the end of the month. It kills a broad spectrum of ectoparasites: Ctenocephalides canis, Ctenocephalides felis, Ixodes ricinus, Dermacentor reticulatus, Rhipicephalus sanguineus, Ixodes hexagonus and Sarcoptes scabiei. The medication can also be used as part of a treatment strategy for Flea Allergy Dermatitis (FAD) and it is indicated for the treatment of sarcoptic mange.

“With Simparica, we bring to the market an advanced parasiticide solution, helping to deliver improved client and patient satisfaction,” says Roberta D’Amore, global marketing lead for Companion Animal Parasiticides at Zoetis. “The chewable tablets are easy to administer and readily accepted by dogs. But more importantly, Simparica helps veterinarians and dog owners minimize the potential risk of protection gaps, as it acts very fast to kill fleas and ticks and performs for 35 days without losing efficacy — well beyond the monthly treatment period.”

The results of a recent market research study conducted for Zoetis by The Link Group1 among dog owners in the U.S., the United Kingdom, France and Australia found that 71% of respondents had given flea or tick medicine to their dog later than it was due, with the average delay varying from 3 to 7 days. Simparica gives veterinarians and forgetful pet owners the peace of mind of continuous, month-long protection.

Efficient Treatment for the Most Common Tick Infestations

The efficacy and safety of Simparica have been demonstrated in a comprehensive program involving more than 1,500 dogs. Ten laboratory studies revealed that the medication protected dogs against weekly re-infestations with the most common ticks found to infest dogs in Europe.2,4 The killing effect against Ixodes ricinus starts within 8 hours after a single oral administration and most ticks are killed within 24 hours.4 Five further studies from the US, the EU and Australia have also shown the effectiveness against infestations with dog fleas and cat fleas, including the KS-1 resistant strain, with killing starting within 3–4 hours after administration and effective control reached within 8 hours. For both types of ectoparasites, efficacy against weekly re-infestations was sustained for at least 35 days.3,4 Overall, treatment was very well tolerated by dogs from a variety of breeds from 8 weeks of age.4

Highlighting the relevance of different tick species in dogs in both rural and urban environments in Europe, Professor Frans Jongejan, director of the Utrecht Centre for Tick-borne Diseases (UCTD), Faculty of Veterinary Medicine, University of Utrecht explained: “Especially Ixodes hexagonus and Dermacentor reticulatus seem to emerge in new habitats. A high and consistent efficacy against all tick species, as well as a rapid speed of kill for the entire treatment interval is an important attribute for any new ectoparasiticide entering the market, both from a veterinarian’s and owner’s perspective.”

Simparica also achieved complete parasitological cure of Sarcoptes scabiei. Client-owned and laboratory dogs were mite-free after two monthly treatments, and clinical signs of sarcoptic mange including alopecia, papules, erythema, pruritus and scaling/crusting markedly improved in Simparica-treated dogs.5

“We are happy to provide veterinarians and dog owners across Europe with this new treatment option discovered and developed by Zoetis scientists,” added Dr Michael Stegemann, senior director of Veterinary Medicine Research and Development at Zoetis. “With its rapid onset, robust duration of activity and very good safety profile, Simparica is the best oral isoxazoline indicated for all four species of ticks in Europe and the two species of fleas, dogs are most frequently infested with. Unlike most treatments, Simparica protects from both types of ectoparasites for the same duration.”

 

About Simparica (sarolaner)

The active substance of Simparica is sarolaner, a new ectoparasiticide in the isoxazoline class, discovered and developed entirely by Zoetis scientists who designed a molecule providing optimized anti-parasite potency, pharmacokinetics and safety profile. It specifically targets the isoxazoline binding site (NCA-II) on the GABA-receptors located in the invertebrate (insects and acarids) central nervous system as well as the glutamate-gated ion channels. Disruption of these receptors prevents the uptake of chloride ions, thus resulting in increased nerve stimulation and death of the target parasite6.

For further information about Simparica, visit the European Medicines Agency website by clicking here.

 

Prescribing information:

Simparica is for oral use, once-monthly in dogs beginning at eight weeks of age.

Tablets can be administered with or without food.

The veterinary medicinal product should be administered at a dose of 2-4mg/kg bodyweight.

 

References

1 The Link Group, Simparica Pet Owner Message Testing, November 2015
2 Geurden T, Becskei C, et al.
3 Six R, Everett W et al.
4 Six R, Geurden T, et al.
5 Becskei, C., De Bock, F.,et al.
6 McTier, TL, Chubb, N, et al.